Конференция в Сан-Франциско
#1Я тут болею гриппом, сижу дома и от нечего делать роюсь в медицинских подписках. Где-то регистрировалась, чтобы получить полный доступ.
В итоге приходит сейчас на почту письмо - конференция по психиатрии в Сан Франциско. Какой-то робот, видимо, посчитал меня не просто читателем, а кем-то покруче.
Вначале хотела удалить, а потом подумала, что кому-то ведь информация может быть полезной (и не только врачам). Есть повод съездить в Сан Франциско.
Красивый город, кстати.
Копирую текст целиком:
Phil Skolnick, Director at the NIDA, NIH to speak at the 2nd Neuropsychiatric Research and Development Conference on September 13-14, 2012 in San Francisco, CA
Register before July 13th to get a 20% off discount!
Dear Colleague,
Phil Skolnick, Ph.D., D.Sc., Director of the Division of Pharmacotherapies & Medical Consequences of Drug Abuse at NIDA, NIH, will be giving the presentation entitled, “Biological Approaches to Treat Substance Use Disorders (SUDs)” at the 2nd Neuropsychiatric Research and Development Conference on September 13-14, 2012 in San Francisco, CA. In his presentation, Dr. Skolnick will highlight recent Recent advances in the development of biologics to treat SUDs, discuss the strengths and limitations of biological approaches, note challenges in clinical trial design using biologics, and offer market opportunities for biologics in the treatment of SUDs.
GTC’s 2nd Neuropsychiatric Research and Development conference is the only neuropsychiatric disorders conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest challenges in the field including novel therapeutic approaches and targets to treat schizophrenia, depression, addiction, autism, brain disorders, dementia, epilepsy and various other neuropsychiatric disorders. GTC’s intimate size of high level delegates also makes it easier to network with key experts in the field such as Charles B. Nemeroff from the University of Miami, Husseini Manji - Global Head of Neuroscience Therapeutics at Janssen, George Garibaldi - SVP and Global Head of Neuroscience Development at F. Hoffmann-La Roche, Mark M. Goodman - Professor at Emory, Clinton D. Kilts - Director at the University of Arkansas, and many more!
To view the agenda, click here.
The 2nd Neuropsychiatric Research and Development conference is part of the 2nd CNS Diseases World Summit, which consists of this and three other tracks:
- 6th Neurodegenerative Conditions Research and Development
- 5th CNS Partnering and Deal-making
- Pain Research and Therapeutics
Sign up for one track or gain access to all 4 by registering for the Summit!
Register 3 people for the price of 2! Use discount code rcdvb.
We look forward to seeing you in San Francisco!
PLENARY KEYNOTE SPEAKERS
Barry Brand, Chief Executive Officer & Director, CeNeRx
Stephen Brannan, M.D., VP and Therapeutic Area Leader for Neuroscience, Clinical Science, Takeda Global Research & Development
George Garibaldi, M.D., Senior Vice President, Global Head of Neuroscience Development, F. Hoffmann-La Roche
Husseini Manji, Global Head, Neuroscience Therapeutic, Janssen Research & Development
Charles B. Nemeroff, M.D., Ph.D., Leonard M. Miller Professor and Chairman, Psychiatry and Behavioral Sciences, University of Miami
DISTINGUISHED SPEAKERS AND MODERATORS
Larry Alphs, Therapeutic Area Leader, Psychiatry, Janssen
David G. Brock, M.D., CIP, Medical Director, Neuronetics
Jonathan Brotchie, Founder and Chief Executive Officer, Atuka
Daniel J. Burch, M.D., Executive Vice President, R&D & Chief Medical Officer, CeNeRx BioPharma
Casey Case, Ph.D., Vice President, Research, SanBio
Benjamin N.R. Cheyette, M.D., Ph.D., Associate Professor, Psychiatry, University of California, San Francisco
De-Maw Chuang, Ph.D., Chief, Section on Molecular Neurobiology, National Institute of Mental Health, National Institutes of Health
George Garibaldi, Global Head of CNS Clinical Development, Hoffmann-La Roche
Mark M. Goodman, Ph.D., Endowed Chair for Imaging Sciences, Professor, Radiology and Imaging Sciences, Psychiatry and Hematology and Oncology, Emory University School of Medicine
Jan Grimm, Ph.D., Chief Scientific Officer, Neurimmune Holding
Geoffrey A. Kerchner, M.D, Ph.D, Assistant Professor of Neurology and Neurological Sciences, Stanford Center for Memory Disorders, Stanford University School of Medicine
Clinton Kilts, Ph.D., Director, Brain Imaging Research Center, Associate Director, Psychiatry Research Institute, University of Arkansas for Medical Sciences
Joel Kramer, Psy.D., Director, Neuropsychology, Memory and Aging Center, University of California, San Francisco
Michael J. O’Neill, BSc, Ph.D., Senior Research Advisor, Neurodegenerative Diseases Drug Hunting Team, Eli Lilly and Company
Kimberly Scearce-Levie, Scientist, Genentech
Phil Skolnick, Director, Division of Pharmacotherapies & Medical Consequences of Drug Abuse, NIDA, NIH
Derek A. Small, President & CEO, Naurex
Hugh Brent Solvason, M.D, Ph.D, Associate Professor, Med Center Line, Psychiatry & Behavioral Science - Psychopharmacology, Stanford School of Medicine
Laurence Tecott, M.D, Ph.D, Professor, University of California, San Francisco
Gabriel Vargas, M.D, Ph.D, Executive Medical Director & Therapeutic Area Head Neuroscience Early Development, Amgen
David Williamson, PhD (ABPP), MBA, Principal Scientific Affairs Liaison, Medical Affairs, Janssen Scientific Affairs
For an updated speaker list, click here.
Register today and receive a 20% discount before July 13th!
Sign up 2 people at the regular price, bring a 3rd person for free! Use discount code rcdvb.
For Business Development & Exhibiting Opportunities contact Maribel Cortes at spex@gtcbio.com
Только рег. взнос что-то очень высокий. Дорогая профессия.